PMPRB Summary of VCUs & Orders - 2004
Click on medicine to view details of VCU
| DATE OF APPROVAL |
MEDICINE |
PATENTEE |
%Above Guidelines |
PRICE REDUCTION1 |
EXCESS REVENUES2 |
PAYMENTS |
PATENT STATUS |
| VCUs |
| Nov. 16, 2004 |
Busulfex |
ESP Pharma |
Over 7 |
Yes - to $359.8928/ampoule |
$144,215.55 |
$144,215.55 |
Expiration 08/2014 |
| July 15, 2004 |
Starnoc |
Servier Canada Inc. |
|
Yes - from $1.00 to $0.4964 and $1.23 to $0.7474 |
$739,739.99 –See VCU |
$739,739.99 |
Expired 06/2007 |
| July 9, 2004 |
Prolastin |
Bayer Inc. |
|
$288 MNE + CPI - See VCU for details |
|
|
Expiration 03/2009 |
| June 25, 2004 |
Fasturtec11 |
Sanofi-Synthelabo Canada Inc. |
|
Yes - $295/vial to $125/vial - See VCU for details |
|
|
Expiration 07/2010; 05/2015 |
| May 6, 2004 |
One-Alpha |
LEO Pharma Inc. |
|
See VCU for details |
$23,049.10 |
$23,049.10 |
Expired 05/2004 |
| ORDER |
1.There are no price reductions in cases where the PMPRB's jurisdiction ceased with the expiry or the dedication (prior to 1995) of the patent.
2. In all cases, all excess revenues were offset through further price reduction and/or payment.
11. Notice of Hearing issued on May 20, 2004.